Debilitated, risk of hypotension, slow metabolizers, or sensitive to olanzapine: initially 150mg every 4 weeks; titrate with caution. Monitor patient post injection for at least 3 hours for ...

This approach aligns with the opinion that long-lasting injectable treatments can improve treatment continuity and outcomes in schizophrenia management. Olanzapine is an atypical antipsychotic and ...

Am J Health Syst Pharm. 2008;65(12):1180-1183. Ultimately, more formalized, high-quality, and clinically applicable studies are necessary to determine the safety of the parenteral combination of ...

Teva’s Phase 3 SOLARIS trial program is evaluating the potential of TEV-'749 and its innovative drug delivery technology as a long-acting injectable (LAI) subcutaneous formulation of olanzapine ...

In addition to positive efficacy results 2, the Phase 3 trial of our long-acting injectable formulation of olanzapine has demonstrated promising potential in addressing the significant challenge ...

Olanzapine 5mg, 10mg, 15mg, 20mg; orally-disintegrating tabs; contains phenylalanine. Bipolar disorder: Monotherapy: initially 10–15mg once daily; may increase by 5mg/day. Concomitant lithium or ...

Importantly, there were no episodes of post-injection delirium/sedation syndrome, or PDSS. Other efforts to develop long-acting olanzapine have fallen flat due to this side effect. There's a huge ...

subcutaneous long-acting injection of the atypical antipsychotic olanzapine for the treatment of schizophrenia. This is the second drug within the partnership with Teva that uses Medincell’s co ...

Administrators in the psychiatry department proposed that concomitantly active orders for both intramuscular olanzapine and parenteral benzodiazepines be prohibited as a matter of policy; this ...

For healthcare providers and patients, PDSS remains a barrier to the widespread use of olanzapine LAI. The requirement for close post-injection monitoring limits the convenience and flexibility of ...

Patient and healthcare professional attitudes and trial experiences with a subcutaneous long-acting injectable olanzapine (TV-44749) for the treatment of schizophrenia Olanzapine LAI (mdc-TJK ...